Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Total Liabilities: $64,400M in FY2025, up 10.8% from a year earlier.
Latest, FY2025
64,400
Period ended Dec 31, 2025
Change on a year earlier
+10.8%
58,120 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗
Reported in Postgres DB + Form 6-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Liabilities ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 64,400 | +10.8% | Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 58,120 | +9.3% | Novartis 20-F (0001370368-25-000004, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 53,195 | -8.3% | Novartis 20-F (0001370368-24-000004, filed 2024-01-31) ↗ |
| FY2022 | Dec 31, 2022 | 58,030 | -9.3% | Novartis 20-F (0001370368-23-000006, filed 2023-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 63,973 | -10.0% | Novartis 20-F (0001370368-22-000010, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 71,112 | +13.2% | Novartis 20-F (0001370368-22-000010, filed 2022-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 62,819 | -6.1% | Novartis 20-F (0001370368-20-000003, filed 2020-01-29) ↗ |
| FY2018 | Dec 31, 2018 | 66,871 | +13.6% | Novartis 20-F (0001370368-19-000002, filed 2019-01-30) ↗ |
| FY2017 | Dec 31, 2017 | 58,852 | +6.6% | Novartis 6-K (0001370368-18-000005, filed 2018-01-24) ↗ |
| FY2016 | Dec 31, 2016 | 55,233 | – | Novartis 6-K (0001370368-18-000005, filed 2018-01-24) ↗ |
Cite this data
StockData. (2026). Novartis Total Liabilities ($M), annual FY2016–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-bs-total-liab
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.